ABSTRACT
INTRODUCTION
Carcinoma of the breast, like other malignancies, is a genetic disease with multiple genetic events leading to the malignant phenotype. A number of oncogenes (neu/ HER-2/ C-erbB-2, int-2, myc) and tumour suppressor genes (p53, Rb) have been implicated in the pathogenesis of breast carcinoma, amongst which p53 tumour suppressor gene is one of the most commonly mutated gene (1) .
The p53 is a 20 Kb gene located on the short arm of chromosome 17 at 17p13.1 locus. It contains 11 exons, first of which is non-coding and some 10 Kb away from the rest (2) . Comparison of the amino acid sequence of p53 gene products from different species has revealed 5 (I-V) highly conserved domains during evolution (2) , which are critical for P53 protein function. The p53 plays a critical role in cell cycle regulation, cellular response to DNA damage and induction of apoptosis. It operates at the G1/S check point and therefore in cells lacking functional p53, replication of damaged DNA with insufficient repair leads to genomic instability. p53 also directly stimulates DNA repair by activating transcription of GADD 45 and binding to ERCC3. If DNA damage is too extensive to be repaired, p53 causes damaged cells to self destruct by triggering apoptosis (3).
Inactivation of p53 gene is one of the most common somatic genetic alterations in most human malignancies including cancers of the breast (3). Most mutations are missense and clustered between 130-290 amino acid residues. Most p53 mutations are localized to the highly conserved domains II, III, IV and V which correspond to amino acid residues 117-142 (exon 4-5), 171-181 (exon 5), 234-258 (exon) and 270-286 (exon 8) respectively. Thus the core highly conserved region i.e. exons 5-8 is the target of the majority of p53 mutations in human malignancies (4) . The p53 gene is mutated in 25-40% of breast carcinoma cases. There is higher than expected incidence of G to T transversions and Guanosine mutations in the non-transcribed strands are a preferred target. This suggests an etiological role of exogenous chemical carcinogens in sporadic breast carcinoma (5) . Mutations in p53 are often but not always accompanied by allele loss at 17p13 (5) . Studies have directly correlated p53 mutations with breast cancer prognosis and it has recently been demonstrated that p53 gene mutations (exons [4] [5] [6] [7] [8] [9] [10] are the single most predictive indicator for recurrence and death in breast cancer. Direct detection of p53 mutations has substantially greater prognostic value than immunohistochemical detection (6, 7, 8) .
In the present study, our aim was to detect mutations in exons 5 and 7 of p53 tumour suppressor gene in human sporadic breast cancers by Polymerase Chain Reaction amplification of the target DNA followed by Single Strand Conformation Polymorphism analysis and study their role as a prognostic indicator. There does not appear to be a breast cancer specific clustering of p53 mutations or "hot spots", but most have been identified in the core region. Exons 5 and 7 were therefore particularly chosen for the study.
MATERIALS AND METHODS

Collection of samples:
Tumour tissue specimens from thirty seven cases of Carcinoma breast were collected from the surgical operation theatre of Lok Nayak Hospital, New Delhi. All the patients of Carcinoma breast underwent modified radical mastectomies and axillary lymph node dissection. p53 studies were done on fresh tissue specimens. A small piece of tumour tissue 0.5-1 cm was dissected free of the adherent normal tissue. The adjacent normal breast tissue and blood of the same patient were taken as the control samples. The tissues were frozen at -70°C until analysis.
DNA extraction from tissue: High molecular weight cellular DNA from breast tissue (cancerous/normal) was extracted by grinding with sea sand and 4ml 1XTE (1 M Tris, 0.5M EDTA pH 8), 2ml lysis buffer (3% SDS in 2 XTE) and digested with proteinase K (100µg/ml, Boehringer Mamheima) followed by routine phenol chloroform isolation (9) and precipitation overnight in 2.5 volume ethanol with 1/10 volume of 3M Sodium Acetate. Vacuum dried DNA pellet was dissolved in TE (Tris-EDTA) and DNA concentration was measured either by mini gel electrophoresis or by spectrophotometric method.
DNA extraction from blood: 5-10ml of peripheral venous blood was collected into heparinised blood vials (15ml; Corning,USA). To this were added 3 volumes of blood lysis buffer (155mM NH 4 Cl, 10mM KHCO 3 , 0.1 mM EDTA pH 8.0), kept on ice for 15 mins and centrifuged at 3000 rpm for 10 mins at 4°C. The lymphocyte cell pellet was suspended in 5ml SE solution (75mM NaCl, 20 mM EDTA pH 8.0) to which was added 1ml 10% SDS and Proteinase K. (100µg/ml) and incubated overnight at 37°C. Standard phenol chloroform extraction and precipitation with alcohol was used to obtain genomic DNA as for tissue biopsies.
PCR Amplification: Amplification of exon 5 and exon 7 of p53 gene was carried out by standard PCR reaction mix containing 10 mM of Tris pH 8.3, 1.5 mM MgCl 2 , 5mM KCl, 20 pmol of each primer, 200µM of each dNTPs (dATP, dCTP, dGTP, dTTP), 2 units of Taq DNA polymerase (Bangalore Genei, India) and 100ng of tumour DNA per 100µL reaction mix was used (20µL from the prepared reaction mix were then used for each sample). The reaction conditions were optimized. Primers were initially denatured at 94°C for 4 min followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec and extension at 72°C for 30 secs. In the last cycle the extension at 72°C was allowed for 5 min. Then 10-15µL of PCR product were electrophoressed on 3% Nusiev Agarose gel along with øx174 Hae III digested DNA molecular weight marker and photographed under a UV transilluminator. The primer sequence of p53 exon 5 and exon 7 used were:
Single Strand Conformation Polymorphism: Analysis of single strand conformational polymorphism was performed by radiolabelling the PCR products following regular amplification of 30 cycles for an additional 10 cycles where dCTP was replaced with [D-p32]dCTP {specific activity, 4000 Ci/mmol; BARC, Mumbai, India} in the PCR mix. Thus for a typical PCR mix of 100µL meant for 10 samples (10µL each), 1µL of [D-p32]dCTP was added, with other reaction components being the same. 1µL of radiolabelled PCR product was diluted with 9 volumes (10 times) of denaturing solution (95% Formamide, 20mM EDTA pH-8, .05% Xylene cyanol and .05% Bromophenol blue), heat denatured for 5 mins at 95°C and then chilled on ice for 5 mins. 3µL of this diluted product was then subjected to non-denaturing gel electrophoresis in a 6% polyacrylamide gel with 10% glycerol. The gel was then run in The amplification of exon 5 and exon 7 of p53 tumour suppressor gene was done in 25µL reaction volume using appropriate p53 exon primers and the amplified product was checked by electrophoresis on 3% ethidium bromide stained agarose gel. Thus for p53 exons 5 and 7, the amplimers obtained in different breast cancer tissue samples and normal control samples were of sizes 184 and 125 bp respectively. DNA from the tumour as well as control samples was utilized for PCR which showed a good amplification of the exons (see Fig 1 and 2) .
SSCP was performed by radiolabelling the PCR products for an additional 10 cycles where dCTP was replaced with [D-p32] dCTP in the reaction mix. Loading of the denatured labeled product on non-denaturating polyacrylamide gel followed by its autoradiography revealed presence of several bands on the autoradiograph. The mutation of exon 5 of the 
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p53 gene was seen as presence of an extra band in SSCP in addition to the other bands which were homogenously present in other tumour as well as in normal control samples.
The electrophoretic mobility shift in the tumour sample of exon 5 was analyzed in comparison to the normal controls.
DISCUSSION
Most p53 gene mutations found in human cancers produce missense proteins with altered or absent transcriptional regulation activities and are associated with high concentration of P53 protein detectable by immunohistochemistry. The loss of p53 function eliminates growth arrest in response to certain DNA damaging agents and enhances the frequency of gene amplification, suggesting a role for p53 in the control of cell cycle check point and in the maintenance of integrity of the genome (10). The p53 gene, according to most studies, is mutated in 25-40% of sporadic breast carcinoma cases. Although there does not appear to be a breast cancer specific clustering of p53 mutations, or "hot spots", within the p53 gene, most have been identified within the highly conserved core region, which is exons 5 to 8. Exon 5 and 7 were therefore particularly chosen for the present study. Although 20% of mutations are outside of exons 5-8, these mutations are predominantly of the null type, resulting in truncated proteins or products of abnormal splicing.
There is a higher than expected incidence of G to T transversions and guanosine mutations in the transcribed strand are a preferred target. This suggests an etiological role of exogenous chemical carcinogens in sporadic breast carcinoma (6) . The world wide incidence of breast cancer varies by at least four fold and exposure to environmental mutagens has been hypothesized to underlie this variation. In support of this hypothesis, cross cultural studies of Japanese women have shown that native populations have a very low risk of breast cancer, and that this risk rises dramatically within one generation of moving to a high risk area, for example the USA (10) . In the present study, a mutation could be detected in only one of the thirty seven cases in exon 5; it is therefore difficult to comment upon the etiology from analysis of the present study.
Most of the studies on p53 mutations in breast carcinoma have used immunohistochemical detection of P53 overexpression, which is only an indirect assay and gives an approximate estimate of mutation frequency. Wild type p53 is generally not detected by this technique because of its short half life i.e. about 6-20 min (12) . It is generally accepted that p53 gene mutations lead to an overexpression/ stabilization or increase in the half life of the protein. Alternatively, p53 may form complexes with E6/E7 (protein coding regions in the genomic organization of HPV) during HPV infection and this p53-E6/E7 complex formation may lead to stabilization of P53 protein till such time that it is degraded through the Ubiquitin pathway (5). It is also not unlikely to find some residual stable P53 during the process of complex formation and degradation. This may be the reason for the observation of overexpression of p53 messenger RNA transcripts detected by immunohistochemistry which are not necessarily due to mutation.
PCR-SSCP and sequencing correlate with each other in 96.5% cases (20) . Although sequencing is the most unambiguous method, it is technically cumbersome and expensive. Therefore DNA analysis by PCR-SSCP was particularly chosen for the study, since there is 100% correlation between band shift in SSCP and mutation of the p53 gene.
More recently, certain studies have directly correlated p53 mutations with breast cancer prognosis. It has been demonstrated that p53 gene mutations (exons 4-10) were the single most predictive indicators for recurrence and death in breast cancer. Exons 5-8 were screened for p53 mutations and it was observed that mutations in only exons 5 and 6 had a significant correlation with high S phase index (21) .
A study by Andersen et al (8) also showed that the highest frequency of p53 mutations in breast carcinoma is in exon 7 per base pair, which were screened by constant denaturant gel electrophoresis and demonstrated a correlation of p53 mutations with adverse prognostic factors and decreased survival. Thoralacius et al (22) analysed only exons 5, 7 and 8 for p53 mutations and showed an association with low estrogen content and high mortality rates. A study by Gentile et al (23) has suggested that missence mutations in the zinc binding domain of the P53 protein contribute substantially to tumour aggressiveness and adverse prognosis.
In contrast to the findings of previous studies which have shown p53 gene mutation as an important prognostic factor in patients with breast carcinoma, no such prognostic role of p53 mutation could be assessed from the present study since mutation was found in only one of the thirty seven cases.
To summarize, thirty seven cases of carcinoma breast were analyzed by PCR-SSCP for mutations in exon 5 and 7 of p53 tumour suppressor gene in the present study. Mutation was found in only one of the thirty seven cases, i.e. in 2.7% of the cases. This is in contrast to the findings of the previous studies where the mutation frequency has been reported to be 13-30% by molecular analysis. This suggests that the occurrence of p53 mutations relatively low in Indian women with breast cancer as there are only few other reported studies about the mutation frequency in p53 gene in the Indian population.
